Commercial Channels

Existing incentives continue to draw in new drug developers; payers begin to look at competitive markets to drive down drug costs

More unusual gyrations as Mylan attempts to quell uprising against its pricing policies

Good Neighbor and Health Mart franchises trade top positions

Presidential politicking adds momentum to the growing backlash, and not just for Mylan

Substantial investments have been made, but beneficial results hard to identify, says ZS Associates

Life sciences marketers contend with a flood of new data sources—and the challenge of integrating them for meaningful results

Applying specialty-pharma techniques to a potentially mass-market drug

Healthcare research firm calls out the alarmist predictions over PCSK9s and other new drugs

Advent joins Thomas Lee Partners in ownership of the clinical, commercial outsourcer

The scale of the cardiovascular market pushes payers to demand quality outcomes data

Bloomberg BusinessWeek rakes over charitable copay programs

Company pursues ‘bench to bedside’ commercialization services

Site opens up a Facebook-like “Pages” to vendors and medical organizations

Managed care organizations are adjusting rapidly to onslaught of specialty products

A raft of new therapies is generating renewed optimism for cancer care, but even as lower-cost biosimilars enter the market, cost is a crippling factor

Policymakers look at alternative payment models in oncology

More healthcare stakeholders line up against the industry

Integrating copay programs with multichannel marketing

Gamifcation software developer touts value of its patient reward system

Double-digit growth (12.2%) for the second year running

KloudScript seeks to backstop local pharmacies with specialty services

Experience--mostly in Europe--indicates a heavy educational burden for patients and physicians

'Customer Experience Tracker' measures success in oncologist interactions